8/1/2013 7:28:04 AM
Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
AstraZeneca is looking at ways to leverage its capacity to make biotech drugs within its MedImmune unit, including a possible move into so-called biosimilars, its chief executive said on Thursday.
Pascal Soriot declined to comment, however, on whether he might be interested in acquiring a biosimilars business such as South Korea's Celltrion.
Help employers find you! Check out all the jobs and post your resume.
comments powered by